The risk of major adverse CV events (MACE) in PsA patients not using disease-modifying antirheumatic drugs (DMARDs) was comparable to that in rheumatoid arthritis (RA) after adjusting for traditional CV risk factors [70]
Disclosures: George Cholankeril: Nothing to Disclose, Yan Liu: Nothing to Disclose, Kavish Patidar: Madrigal Pharmaceuticals: Medical Advisory Board, Tzu-Hao Lee: Nothing to Disclose, Ruben Hernaez: Nothing to Disclose, Abbas Rana: Nothing to Disclose, Thom Taylor: Nothing to Disclose, Jennifer Kramer: Nothing to Disclose, Hashem El-Serag: Nothing to Disclose, Fasiha Kanwal: Nothing to Disclose 1167 CUMULATIVE DOSE AND DURATION OF STATIN USE ARE ASSOCIATED WITH A REDUCED RISK OF LIVER CANCER AFTER ADJUSTING FOR AGE, FIB-4 SCORE, AND PRIOR CIRRHOSIS DIAGNOSIS IN MASLD PATIENTS
Where Barkleys health journey stands now Barkleys progress has not been perfectly linear
Mazdutide A phase II, randomized, double-blind, placebo-controlled trial showed moderate weight loss with mazdutide in Chinese patients with overweight or obesity without T2DM)
:max_bytes(150000):strip_icc()/VWH-GettyImages-2158519129-372ed708fbbb4c6e9f472a8218cd52ee.jpg)
